VitriVax

Vaccine company developing a single-dose Lyme disease vaccine candidate and the ALTA vaccine platform.

ShareLink copied

The record

Vertical
Vaccines
Stage
Series C

What they do

VitriVax is a vaccine company with a single-dose Lyme disease vaccine candidate and an ALTA vaccine platform. On November 18, 2026, it announced an oversubscribed $87 million Series C co-led by F-Prime, NEA, RA Capital Management and Sanofi Ventures, with Eli Lilly and other existing investors participating. The financing will support taking the Lyme vaccine candidate into first-in-human trials and expanding the pipeline.

Investors

  • F-Prime
  • NEA
  • RA Capital Management
  • Sanofi Ventures
  • Eli Lilly

History and progression

How VitriVax got here, step by step.

  1. 18 November 2026

    $87 million Series C

    VitriVax announced an oversubscribed $87 million Series C co-led by F-Prime, NEA, RA Capital Management and Sanofi Ventures, with Eli Lilly and other existing investors participating, to advance its single-dose Lyme vaccine candidate into first-in-human trials and expand its pipeline.

Key products

Single-dose Lyme disease vaccine candidate
Candidate intended to advance into first-in-human trials with the November 2026 financing.
ALTA
VitriVax vaccine platform.

Recent news

  1. 18 November 2026

    VitriVax announces $87 million Series C financing

Related companies

Your daily HealthTech Signal

No hype. Just signal.

Get the latest HealthTech news, understand why it matters, and see where the industry is headed.

5-minute read Delivered daily Unsubscribe anytime

Read by teams at companies like:

Mayo Clinic logoMayo ClinicCleveland Clinic logoCleveland ClinicJohns Hopkins logoJohns HopkinsKaiser Permanente logoKaiser PermanenteEpic logoEpicPhilips logoPhilipsMedtronic logoMedtronicGE HealthCare logoGE HealthCare

Is this your company? Get a Verified profile